Based on the Alkem Laboratories Limited stock forecast from 1 analysts, the average analyst target price for Alkem Laboratories Limited is INR 3,850.00 over the next 12 months. Alkem Laboratories Limited’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Alkem Laboratories Limited is Slightly Bullish , which is based on 8 positive signals and 6 negative signals. At the last closing, Alkem Laboratories Limited’s stock price was INR 4,734.30. Alkem Laboratories Limited’s stock price has changed by -1.87% over the past week, -6.16% over the past month and +42.07% over the last year.
No recent analyst target price found for Alkem Laboratories Limited
No recent average analyst rating found for Alkem Laboratories Limited
Company Overview Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. Alkem Laboratories Limited was incorporated in 1973 and is headquartered in Mumbai, India. Address: Devashish Building, Mumbai, India, 400013 Read Less
Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilar...Read More
Frequently Asked Questions About Alkem Laboratories Limited (ALKEM:NSE) Stock
Based on ratings from 1 analysts Alkem Laboratories Limited's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has buy, sell and 1 hold ratings.
ALKEM:NSE stock's dividend yield is 0.95%.
Our analysis grades ALKEM:NSE stock's dividend yield at B. This means that ALKEM:NSE stock's dividend yield is above 83% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this ALKEM:NSE may be a good dividend stock for its sector.
Based on targets from 1 analysts, the average taret price for ALKEM:NSE is INR 3,850.00 over the next 12 months. The maximum analyst target price is INR 3850 while the minimum anlayst target price is INR 3850.
ALKEM:NSE stock's Price/Earning ratio is 35.84.
Our analysis grades ALKEM:NSE stock's Price / Earning ratio at F. This means that ALKEM:NSE stock's Price/Earning ratio is above 52% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this ALKEM:NSE may be a overvalued for its sector.
The last closing price of ALKEM:NSE's stock was INR 4,734.30.
The most recent market capitalization for ALKEM:NSE is INR 566.06B.
Based on targets from 1 analysts, the average taret price for ALKEM:NSE is projected at INR 3,850.00 over the next 12 months.
This means that ALKEM:NSE's stock price may go down by -18.68% over the next 12 months.
We can't find any ETFs which contains Alkem Laboratories Limited's stock.
As per our most recent records Alkem Laboratories Limited has 16,871 Employees.
Alkem Laboratories Limited's registered address is Devashish Building, Mumbai, India, 400013.
You can get more information about it from Alkem Laboratories Limited's website at https://www.alkemlabs.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ALKEM:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
